HSHao Shu

Hao Shu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hao Shu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prevalence, contributing factors, and clinical impact of apathy in Parkinson's disease

    by Lihua Gu, Pengcheng Zhang, Yanjuan Wang, Yinwei Zhu, Hongfei Li, Hao Shu


  • Correlation between plasma epidermal growth factor and follow-up cognitive decline in Parkinson’s disease

    by Lihua Gu, Pengcheng Zhang, Wenchao Zuo, Hao Shu, Pan Wang

    Background Epidermal growth factor (EGF) has been shown to have neuroprotective effects in Parkinson’s disease (PD). However, there is a lack of research on the association between plasma EGF levels and cognitive impairments in PD patients. Methods The study included 135 PD patients. Plasma EGF concentrations were measured. PD patients without cognitive impairment were followed up for clinical assessment at an average of 2 ± 0.6 years. Results PD patients with cognitive impairment (PD-CI) had lower baseline plasma EGF concentrations compared to PD patients without cognitive impairment. Linear regression analysis demonstrated a significant correlation between baseline plasma EGF concentrations and baseline Montreal Cognitive Assessment (MoCA) and Digit Symbol Substitution Test (DSST) scores in PD patients. However, no significant association was found between plasma EGF concentrations and Hopkins Verbal Learning Test-Delayed Recall (HVLT-DR), Semantic Fluency Test (SFT), Clock Drawing Test (CDT), Trail Making Test (TMT) A, or TMT B scores. Furthermore, logistic regression analysis revealed that baseline plasma EGF concentrations were associated with cognitive decline in PD patients without cognitive impairment in adjusted regression models (HR 0.977, 95% CI 0.955–0.999, p = 0.045), after adjusting for various factors. The area under the curve (AUC) for cognitive decline at follow-up time was 0.704 (95% CI 0.600-0.809), and the optimal cut-point for baseline plasma EGF concentrations was determined to be 49.56 pg/mL, with a sensitivity of 49.3% and specificity of 92.3%. Conclusions In conclusion, our study found a correlation between baseline plasma EGF concentrations and cognitive dysfunction in PD.


  • Open Access

    Predictive value of serum neurofilament light chain for cognitive impairment in Parkinson’s disease

    by Lihua Gu, Pengcheng Zhang, Rui Gao, Hao Shu, Pan Wang

    Background: Neurofilament light chain (NfL) has recently emerged as a key indicator of neurodegeneration. In this study, our hypothesis is that the levels of blood-derived NfL and its accumulation during the Parkinson’s disease (PD) progression could serve as a potential biomarker for predicting subsequent cognitive decline. To investigate this, we conducted a study utilizing a large single-center cohort.Methods: The study included 193 participants, consisting of 106 cognitively normal PD (PD-CN) patients and 87 normal controls (NC) individuals. Serum NfL concentrations were measured. PD patients were followed up for clinical assessment at an average of 2 ± 0.6 years.Results: The serum NfL levels were significantly higher in PD-CN patients compared to NC. PD-CN patients and NC at follow-up time exhibited higher serum NfL levels compared to those at baseline. PD patients with high serum NfL levels were found to have a higher likelihood of transitioning from normal cognition to mild cognitive impairment (MCI) or dementia (Hazard ratio (HR) 1.107, 95% confidence intervals (CI) 1.010–1.213, p = 0.030). The area under the curve (AUC) for PD-CN conversion to MCI or dementia at follow-up time was determined to be 0.684 (95% CI 0.569–0.799).Conclusion: In conclusion, our study found that PD patients have significantly higher levels of serum NfL compared to individuals without PD. Furthermore, serum NfL levels increase as PD progresses and can predict cognitive impairment within a 2-year timeframe. Serum NfL may serve as a feasible, non-invasive biomarker of cognitive progression in PD. However, further studies and functional experiments are needed to validate these findings.


  • Association between serum IGF‑1 levels and non-motor symptoms in Parkinson’s disease

    by Lihua Gu, Pengcheng Zhang, Wenchao Zuo, Hao Shu, Pan Wang

    Aims We aimed to measure serum insulin-like growth factor 1 (IGF-1) levels in Parkinson’s disease (PD) patients and assess their correlation with non-motor symptoms (NMS). Background Emerging evidence suggests that abnormal levels of IGF-1 play a crucial role in the development of PD. Objective Further systematic research is needed to explore the potential roles of abnormal IGF-1 levels in NMS of PD. Methods The study enrolled a total of 129 PD patients and 130 healthy controls (HCs). Within the PD cohort, 74 patients were classified as being in the early stage, while 55 were in the moderate stage. Results This study found no significant difference in serum IGF-1 levels between PD patients and HC. Further analysis revealed no significant difference in IGF-1 levels between early-stage PD and those in the moderate stages. Linear regression analysis indicated a significant association between serum IGF-1 levels and Nonmotor Symptom Scale (NMSS) scores in PD patients. Linear regression analysis revealed significant correlations between serum IGF-1 levels and general cognitive function, information processing speed, and executive function in PD patients. Furthermore, lower serum IGF-1 levels were associated with fatigue in PD patients. Conclusions In summary, our study suggests a potential association between serum IGF-1 levels and specific NMS in patients with PD. These findings highlight the importance of long-term follow-up studies to determine whether serum biomarkers can serve as valuable tools for early detection of NMS in PD.


  • Open Access

    Association of the interleukin 1 beta gene and brain spontaneous activity in amnestic mild cognitive impairment

    by Liying Zhuang, Xiaoyan Liu, Xiaohui Xu, Chunxian Yue, Hao Shu, Feng Bai, Hui Yu, Yongmei Shi, Zhijun Zhang

    Purpose: The inflammatory response has been associated with the pathogenesis of Alzheimer’s disease (AD). The purpose of this study is to determine whether the rs1143627 polymorphism of the interleukin-1 beta (IL-1β) gene moderates functional magnetic resonance imaging (fMRI)-measured brain regional activity in amnestic mild cognitive impairment (aMCI). Methods: Eighty older participants (47 with aMCI and 33 healthy controls) were recruited for this study. All of the participants were genotyped for variant rs1143627 in the IL1B gene and were scanned using resting-state fMRI. Brain activity was assessed by amplitude of low-frequency fluctuation (ALFF). Results: aMCI patients had abnormal ALFF in many brain regions, including decreases in the inferior frontal gyrus, the superior temporal lobe and the middle temporal lobe, and increases in the occipital cortex (calcarine), parietal cortex (Pcu) and cerebellar cortex. The regions associated with an interaction of group X genotypes of rs1143627 C/T were the parietal cortex (left Pcu), frontal cortex (left superior, middle, and medial gyrus, right anterior cingulum), occipital cortex (left middle lobe, left cuneus) and the bilateral posterior lobes of the cerebellum. Regarding the behavioral significance, there were significant correlations between ALFF in different regions of the brain and with the cognitive scores of each genotype group. Conclusions: The present study provided evidence that aMCI patients had abnormal ALFF in many brain regions. Specifically, the rs1143627 C/T polymorphism of the IL1B gene may modulate regional spontaneous brain activity in aMCI patients.